Multiple Myeloma

Following ASCO 2024, Samer Al'Hadidi, MD, discusses recent updates from the PERSEUS trial evaluating the role of testing for minimal residual disease (MRD) in guiding treatment for relapsed/refractory multiple myeloma.

Experts on multiple myeloma provide comprehensive insights on treatment spacing and step-up dosing practices and discuss the long-term utilization of bispecific antibodies.

A panel of experts in multiple myeloma discussed strategies for sequencing novel bispecific antibodies and CAR T-cell therapies for patients with relapsed/refractory disease.

Experts in multiple myeloma discussed the evolving role of CAR T-cell therapy for patients with relapsed/refractory disease.

The expert panel shares clinical insights on sequencing CAR T-cell therapies and bispecific antibodies for patients with relapsed/refractory multiple myeloma.

Naresh Bumma, MD, and Hans Lee, MD, recap recent updates on the MagnetisMM-30 an MagnetisMM-32 studies investigating elranatamab, a BCMA-directed bispecific antibody.

Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.

The panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.

The panel concludes by offering key takeaways on the treatment of patients with relapsed/refractory multiple myeloma who receive CAR T-cell therapy.

Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.

Samer Al'Hadidi, MD, provides an overview of recent updates presented at ASCO 2024 from the MajesTEC-1 trial evaluating teclistamab in patients with relapsed/refractory multiple myeloma.

Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.

Hans Lee, MD, discusses recent updates from the MonumenTAL-2 study investigating talquetamab in patients with relapsed/refractory multiple myeloma.

Experts on multiple myeloma provide clinical insights on unmet needs associated with CAR T-cell therapy, focusing on patient access across academic and community settings.

The panel provides clinical insights on talking with patients about complications associated with CAR T-cell therapy.

Second interim analysis findings from CARDITUDE-4 show no new safety signals with cilta-cel in relapsed, lenalidomide-refractory multiple myeloma.

Continuing the discussion on supportive care strategies, the panel discusses the management of cytopenias and HLH/MAS following CAR T-cell therapy.

Experts on multiple myeloma provide clinical insights on supportive care strategies for patients experiencing infections or secondary malignancies following CAR T-cell therapy.

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, discuss the clinical implications of data from MajesTEC-1 and provide key takeaways on the evolving relapsed/refractory multiple myeloma treatment landscape.

Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.

Hematologic oncology specialists provide an overview of the study design of the PERSEUS trial and outline the role of MRD negativity in the treatment of patients with multiple myeloma.

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD, discuss the overall frontline treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).

Focusing on recent approvals in earlier lines of relapsed/refractory multiple myeloma, the panel has a comprehensive discussion on the CARTITUDE-4 and KarMMa-3 studies and shares clinical insights on administering CAR T-cell therapy and monitoring patients.

A panel of experts on multiple myeloma introduce themselves and discuss recent data presented on the phase 3 IMROZ trial for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

A panel of oncologists in academic and community settings discuss patient monitoring practices following CAR T-cell infusions, with a focus on neurotoxicities.